Drug Profile
Research programme: oxytocin receptor agonist - Wyeth
Alternative Names: WAY-267464Latest Information Update: 29 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Small molecules
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 29 Sep 2011 No development reported - Preclinical for Anxiety disorders in USA (unspecified route)
- 21 Oct 2009 Pharmacodynamics data from a preclinical trial in Anxiety disorders presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
- 15 Oct 2009 Wyeth has been acquired by Pfizer